

**National Stock Exchange of India Limited****DEPARTMENT : LISTING****Download Ref. No.: NSE/CML/43650****Date : February 25, 2020****Circular Ref. No.: 0200/2020**

To All Members,

**Sub: Recommencement of trading in equity shares of Bafna Pharmaceuticals Limited post capital reduction pursuant to Resolution Plan approved by NCLT vide order dated February 01, 2019**

In pursuance of Regulation 3.1.1 of the National Stock Exchange (Capital Market) Trading Regulations Part A, it is hereby notified that the list of securities further admitted to dealings on the National Stock Exchange (Capital Market segment) with effect from February 27, 2020 and the designated security codes thereof shall be as specified in annexure.

In pursuance of Regulation 2.5.5 of the National Stock Exchange (Capital Market) Trading Regulations Part A, it is hereby notified that the respective lot sizes in respect of securities above shall be as specified in Annexure I. For the purpose of trading on the system, the security shall be identified only by its designated codes and trading in such securities shall be in such lot sizes as specified in Annexure.

**Members are requested to note that the above security will be part of pre-open session as per SEBI circular no. CIR/MRD/DP/01/2012 & CIR/MRD/DP/02/2012 dated January 20, 2012.**

This circular shall be effective from February 27, 2020.

**For and on behalf of  
National Stock Exchange of India Limited**

**Rajendra Bhosale  
Manager**

**Toll Free Number  
1800 266 0058**

### Annexure I

#### BAFNA PHARMACEUTICALS LIMITED

|                          |                                                                                                                                                                  |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Symbol                   | BAFNAPH                                                                                                                                                          |
| Name                     | Bafna Pharmaceuticals Limited                                                                                                                                    |
| Series                   | BE - Trade for Trade                                                                                                                                             |
| Security Description     | Equity Shares of Rs. 10/- each post capital reduction pursuant to Resolution Plan approved by National Company Law Tribunal, vide order dated February 01, 2019. |
| ISIN*                    | INE878I01022                                                                                                                                                     |
| Face Value (In Rs.)      | 10                                                                                                                                                               |
| Paid-up Value (In Rs.)   | 10                                                                                                                                                               |
| No. of securities        | 2365634                                                                                                                                                          |
| Distinctive number range | 1 to 2365634                                                                                                                                                     |
| Market lot               | 1                                                                                                                                                                |
| Pari Passu               | Yes                                                                                                                                                              |
| Remarks                  | * The securities shall be available for trading in Series 'BE' till further notice.                                                                              |
| Lock-in Details          | As per Annexure II                                                                                                                                               |

### Annexure II

| No. of Shares         | Distinctive Numbers Range |         | Date upto which lock-in |
|-----------------------|---------------------------|---------|-------------------------|
|                       | From                      | To      |                         |
| 500000                | 1865635                   | 2365634 | 31-May-2020             |
| <b>Total - 500000</b> |                           |         |                         |

|                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Address of Registered Office of the Company:</b><br><b>Bafna Pharmaceuticals Limited</b><br>"BAFNA TOWERS" 299,<br>Thambu Chetty Street,<br>Chennai-600 001, India.<br>Email id: <a href="mailto:cs@bafnapharma.com">cs@bafnapharma.com</a> | <b>Contact Person:</b> - Mr. Jitendra Kumar Pal<br><b>Website:</b> <a href="http://www.bafnapharma.com">www.bafnapharma.com</a><br><b>Email:</b> <a href="mailto:cs@bafnapharma.com">cs@bafnapharma.com</a><br><b>Financial year:</b> 1 <sup>st</sup> April to 31 <sup>st</sup> March |
| <b>Address of Registrar and Share Transfer Agents:</b><br>Cameo Corporate Services Limited<br>Subramanian Building, No.1, Club House Road, Chennai – 600002, India<br>Tel: 044-28460390-94                                                     |                                                                                                                                                                                                                                                                                       |

\* Currently equity shares allotted in dematerialized mode have been credited under the temporary ISIN (IN8\*\*\*\*\*) in accordance with the SEBI circular no. CIR/MRD/DP/21/2012 dated August 02, 2012 and CIR/MRD/DP/24/2012 dated September 11, 2012 regarding activation of ISIN in case of additional issue of shares / securities.

**The brief details about the Resolution Plan approved by NCLT is as follows:**

1. As per the Resolution Plan approved by Hon'ble NCLT, the share capital of Bafna Pharmaceuticals Limited shall be reduced to 10%. Hence, the existing 2,36,56,335 equity shares shall reduce to 23,65,634 equity shares.
2. Bafna Pharmaceuticals Limited has fixed Record Date as August 27, 2019 for the purpose of determining the eligible equity shareholders whose equity shares shall stand reduced, pursuant to the Resolution Plan approved by the Hon'ble National Company Law Board Tribunal, Chennai Bench vide its Order dated February 01, 2019.